通策医疗股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12层、23层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road. Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhepa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn) "进行查验 报告编码:浙250QH07F3P 目 录 | | 页 次 | | --- | --- | | 一、审计报告 | 1-5 | | 二、财务报表 | 6-17 | | (一) 合并资产负债表 | 6-7 | | (二) 合并利润表 | 8 | | (三) 合并现金流量表 | 9 | | (四) 合并所有者权益变动表 | 10-11 | | (五) 母公司资产负债表 | 12-13 | | (六) 母公司利润表 | 14 | | (七) 母公司现金流量表 | 15 | | (八) 母公司所有者权益变 ...

通策医疗股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 报告编码:浙25VC3G5GG8 ther 内部控制审计报告 中汇会审[2025]5269号 通策医疗股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了通策医疗股份有限公司(以下简称通策医疗公司)2024年12月31日的财务 报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是通策医疗 公司董事会的责任。 二、注册会计师的责 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 744.61 million, an increase of 5.11% compared to CNY 708.44 million in the same period last year[5]. - Net profit attributable to shareholders was CNY 183.93 million, reflecting a growth of 6.22% from CNY 173.22 million year-on-year[5]. - Basic and diluted earnings per share were both CNY 0.41, representing a 5.13% increase from CNY 0.39 in the same period last year[5]. - Total operating revenue for Q1 2025 reached ¥744,611,704.47, an increase of 5.5% compared to ¥708,442,365.10 in Q1 2024[21]. - Net profit for Q1 2025 was ¥216,103,399.66, representing a 5.9% increase from ¥203,864,140.15 in Q1 2024[21]. - The net profit attributable to shareholders of the parent company was ¥183,925,013.61, compared to ¥173,151,359.78 in the same period last year, reflecting a growth of 6.5%[22]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.41, up from ¥0.39 in Q1 2024[22]. Cash Flow - The net cash flow from operating activities reached CNY 147.69 million, up 13.93% from CNY 129.41 million in the previous year[5]. - The company reported a total cash flow from operating activities of ¥670,695,631.81 for Q1 2025, compared to ¥646,195,492.97 in Q1 2024[24]. - The net cash flow from operating activities was $147,693,433.62, an increase from $129,630,596.75 in the previous period, reflecting a growth of approximately 13.5%[25]. - The total cash inflow from investment activities was $5,273,912.51, down from $8,010,488.89, indicating a decrease of about 34.3%[25]. - The net cash flow from financing activities was -$106,653,416.80, worsening from -$64,356,040.91, representing a decline of approximately 65.5%[26]. - The cash inflow from operating activities totaled $677,575,609.67, compared to $653,342,191.28, reflecting an increase of about 3.7%[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6.26 billion, a 1.31% increase from CNY 6.18 billion at the end of the previous year[6]. - The company's current assets totaled RMB 935,692,569.16, up from RMB 917,629,396.66 at the end of 2024, indicating an increase of about 1.36%[15]. - The total non-current assets reached RMB 5,327,679,518.15, compared to RMB 5,264,459,245.73 previously, reflecting an increase of approximately 1.2%[16]. - Total liabilities decreased to ¥1,689,279,715.45 in Q1 2025 from ¥1,822,999,066.66 in Q1 2024, indicating a reduction of approximately 7.3%[17]. - The total liabilities include accounts payable of RMB 128,439,580.55, which decreased from RMB 136,650,854.56, indicating a reduction of about 6.5%[16]. - The company reported a decrease in employee compensation payable from RMB 39,474,780.64 to RMB 12,555,784.59, a significant drop of approximately 68.2%[16]. Equity - Shareholders' equity attributable to the parent company was CNY 4.21 billion, up 4.51% from CNY 4.03 billion at the end of the previous year[6]. - Total equity increased to ¥4,574,092,371.85 in Q1 2025 from ¥4,359,089,575.73 in Q1 2024, marking an increase of about 4.9%[17]. - The total equity of the company is not explicitly stated but can be inferred from the total assets and liabilities, indicating a stable financial position[15][16]. Strategic Developments - The company completed the acquisition of 100% equity in Hangzhou Haiyin Technology Co., Ltd. in October 2024, which will be reflected in the financial statements[7]. - The company has not reported any significant changes in shareholder structure or major strategic shifts during the reporting period[14]. Other Financial Metrics - The company reported a significant increase in contract liabilities by 251.35%, primarily due to an increase in advance rental payments[10]. - The net cash flow from investing activities decreased by 57.07%, mainly due to cash payments for the construction of fixed assets and intangible assets[10]. - Cash received from sales of goods and services in Q1 2025 was ¥670,695,631.81, an increase from ¥646,195,492.97 in Q1 2024[24]. - The company's long-term borrowings were reported at ¥169,000,000.00, reflecting a strategic focus on managing debt levels[17]. - Cash outflows for investment activities totaled $69,481,305.03, significantly lower than $157,782,538.09 from the previous period, showing a reduction of approximately 56%[25]. - Cash paid for employee compensation was $316,528,548.52, up from $304,031,478.13, indicating an increase of approximately 4.1%[25]. - The cash outflow for taxes paid was $27,155,619.42, a decrease from $37,916,356.61, representing a reduction of about 28.4%[25]. - The net cash flow from investment activities was -$64,207,392.52, an improvement from -$149,772,049.20, indicating a reduction in losses of approximately 57.1%[25].

Financial Performance - The total operating revenue for 2024 was approximately ¥2.87 billion, representing a 0.96% increase compared to ¥2.85 billion in 2023[19]. - The net profit attributable to shareholders for 2024 was approximately ¥501.43 million, a slight increase of 0.20% from ¥500.44 million in 2023[19]. - The cash flow from operating activities for 2024 was approximately ¥763.41 million, showing a decrease of 9.23% compared to ¥841.02 million in 2023[19]. - The total assets as of the end of 2024 were approximately ¥6.18 billion, an increase of 1.98% from ¥6.06 billion at the end of 2023[19]. - The net assets attributable to shareholders increased by 5.58% to approximately ¥4.03 billion in 2024, up from ¥3.81 billion in 2023[19]. - The basic earnings per share for 2024 remained at ¥1.12, unchanged from 2023[20]. - The weighted average return on equity for 2024 was 12.80%, a slight decrease from 12.91% in 2023[20]. Operational Highlights - The annual outpatient volume reached 3.5334 million visits, representing a year-on-year increase of 5.37%[31]. - The company operates 89 medical institutions, with a total of 4,324 medical staff and over 26,000 square meters of operating space[31]. - The gross margin and net margin for 2024 were 39% and 20%, respectively, despite challenges from consumer downgrade and dental implant procurement policies[36]. - The company added 3 new "Dandelion" branches in 2024, bringing the total to 44, covering all 11 prefecture-level cities in Zhejiang Province[41]. - Approximately 60% of the opened "Dandelion" hospitals achieved a break-even point, indicating effective operational management strategies[41]. Strategic Initiatives - The company plans to focus on cost control, digital upgrades, and resource integration to enhance operational efficiency[38]. - The establishment of the Case Manager (CM) management center aims to enhance customer service efficiency and resource allocation, optimizing the entire process from demand identification to resolution[45]. - The AI platform, MindHub, supports over 60 medical AI modules, facilitating flexible integration of various AI models for business and process transformation[48]. - The company is expanding its market presence through a combination of self-built, acquisition, and franchise models[52]. - The company anticipates a dual-driven strategy of technology leadership in high-end markets and rapid penetration in lower-tier markets to maintain its industry-leading position[67]. Research and Development - The company’s R&D expenses increased by 5.94% to 58.95 million RMB, reflecting ongoing investment in new technologies[70]. - The number of R&D personnel is 394, accounting for 6.33% of the total workforce[87]. - The deployment of AI-driven "AI Expert" systems has improved diagnostic efficiency, achieving an accuracy rate of over 95% in automatic identification of dental issues[115]. - The "Zijingang AI Diagnostic Model" 3.0 version will include new features for intelligent positioning and 3D reconstruction, improving diagnostic accuracy[116]. Corporate Governance - The company has established a robust internal control and risk management system to safeguard investor interests[134]. - The company actively engages with investors through various channels, including hotlines and email responses[135]. - The company has a diverse board with members holding various professional backgrounds, including finance, law, and healthcare, enhancing its governance structure[140]. - The company has implemented a stock distribution plan to incentivize its executives and align their interests with shareholders[138]. Environmental Responsibility - The company has invested 100,000 RMB in environmental protection during the reporting period[171]. - The company has established strict wastewater treatment protocols to ensure compliance with national standards before discharge[173]. - The company has committed to reducing carbon emissions through various measures, including energy-saving practices and environmental assessments for construction projects[175]. Market Expansion - The company is focusing on expanding its presence in third and fourth-tier cities, leveraging local service capabilities for competitive advantage[104]. - The company is enhancing its digital capabilities, aiming for 100% cross-hospital access to patient records by integrating HIS, CRM, and quality control platforms[114]. - The company has signed an acquisition agreement for the Loudi Dental Hospital, with a profit commitment of no less than 4 million CNY, 5 million CNY, and 6 million CNY for the years 2024, 2025, and 2026 respectively, totaling at least 15 million CNY over three years[179]. Compliance and Legal Matters - The company has completed compliance rectification and will enhance adherence to securities laws and regulations, aiming for improved information disclosure quality[186]. - The company has not faced any major litigation or arbitration matters during the reporting period[184]. - The company has not encountered any delisting risks or significant violations during the reporting period[184].

本人作为通策医疗股份有限公司（以下简称"公司"）的独立董事，本人严格按 照《中华人民共和国公司法》《关于在上市公司建立独立董事制度的指导意见》《上 市公司治理准则》等规章和《公司章程》等规定，本着"恪尽职守、勤勉尽责"的工 作态度，认真出席股东大会和董事会会议，认真审议董事会各项议案， 积极参加现 场考察，并基于独立立场对相关事项发表独立客观的意见，切实维护了公司和全体股 东的合法利益，对促进董事会的科学决策、公司的规范运作和高质量发展起到了积极 作用。现将2024年度的履职情况报告如下： （一）个人履历 李敏：男，1980年出生，中国国籍，无境外居留权，民革党员，北京大学法 学学士、澳门科技大学综合法学硕士。擅长民商事争议解决及公司法律事务、国 内明星及经纪公司企业法律顾问、海外资产配置等。现任浙江泽大律师事务所高 级合伙人、国际投资与资产管理工作室主任。 （二）独立性说明 作为公司的独立董事，本人未在公司担任除独立董事外的其他职务，直系亲属、主 要社会关系均不在公司或其附属企业任职，没有为公司或其附属企业提供财务、法律、 咨询等服务。本人具有《上市公司独立董事规则》《上海证券交易所科创板上市公司自 律监管 ...

本人作为通策医疗股份有限公司（以下简称"公司"）的独立董事，本人严格按 照《中华人民共和国公司法》《关于在上市公司建立独立董事制度的指导意见》《上 市公司治理准则》等规章和《公司章程》等规定，本着"恪尽职守、勤勉尽责"的工 作态度，认真出席股东大会和董事会会议，认真审议董事会各项议案，积极参加现场 考察，并基于独立立场对相关事项发表独立客观的意见，切实维护了公司和全体股东 的合法利益，对促进董事会的科学决策、公司的规范运作和高质量发展起到了积极作 用。现将2024年度的履职情况报告如下： （一）个人履历 王绪强：男，1963年出生，中国国籍，无境外居留权，中共党员，浙江财经 大学副教授、税务师，从事税收政策运用实务、财务会计实务，出版发表多部（ 篇）财税、财会类文章著作，尤其擅长企业涉税财务合规运作。现任三门三友科 技有限公司、前进暖通科技有限公司独立董事。 （二）独立性说明 作为公司的独立董事，本人未在公司担任除独立董事外的其他职务，直系亲属、主 要社会关系均不在公司或其附属企业任职，没有为公司或其附属企业提供财务、法律、 咨询等服务。本人具有《上市公司独立董事规则》《上海证券交易所科创板上市公司自 律监管 ...

本人作为通策医疗股份有限公司（以下简称"公司"）的独立董事，本人严格按 照《中华人民共和国公司法》《关于在上市公司建立独立董事制度的指导意见》《上 市公司治理准则》等规章和《公司章程》等规定，本着"恪尽职守、勤勉尽责"的工 作态度，认真出席股东大会和董事会会议，认真审议董事会各项议案，积极参加现场 考察，并基于独立立场对相关事项发表独立客观的意见，切实维护了公司和全体股东 的合法利益，对促进董事会的科学决策、公司的规范运作和高质量发展起到了积极作 用。现将2024年度的履职情况报告如下： （一）个人履历 刘曙峰：男，1970年出生，中国国籍，无境外居留权，北京大学，光华管理 学院硕士，从事企业管理、金融科技领域，现任恒生电子股份有限公司董事长。 （二）独立性说明 作为公司的独立董事，本人未在公司担任除独立董事外的其他职务，直系亲属、主 要社会关系均不在公司或其附属企业任职，没有为公司或其附属企业提供财务、法律、 咨询等服务。本人具有《上市公司独立董事规则》《上海证券交易所科创板上市公司自 律监管指引第1号——规范运作》《公司章程》及《独立董事工作制度》所要求的独立 性和担任公司独立董事的任职资格，能够确保客观 ...

证券简称：通策医疗 证券代码：600763 编号：临 2025-005 通策医疗股份有限公司 关于预计 2025 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 根据《公司章程》的相关规定，本次关联交易事项无需提交公司股东大 会审议； ● 本次关联交易事项将对公司的经营、持续发展带来积极的影响，未损害 上市公司及股东的利益，亦未对本公司的独立性产生重大影响。 一、 公司日常关联交易基本情况 （一）日常关联交易履行的审议程序 通策医疗股份有限公司（以下简称"公司"）召开第十届董事会第九次会议 和第十届监事会第八次会议，审议通过《关于预计 2025 年度日常关联交易的议 案》，表决结果：以同意 4 票、反对 0 票、弃权 0 票，关联董事王毅女士、黄浴 华女士、吕紫萱女士回避了表决。 1 | | 浙江通策壹号投资合伙企业（有限合 伙）下属子公司 | 100 | 45.94 | | | --- | --- | --- | --- | --- | | | 浙江通策眼科医院投资管理有限公 ...

通策医疗股份有限公司（以下简称"公司"）聘请中汇会计师事务所（特殊 普通合伙）（以下简称"中汇会计师事务所"或"中汇所"）作为公司 2024 年度 出具审计报告的会计师事务所。根据财政部、国务院国有资产监督管理委员会、 中国证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办 法》，公司对中汇会计师事务所在 2024 年度的审计工作的履职情况进行了评估。 具体情况如下： 一、会计师事务所的情况 （一）基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 组织形式：特殊普通合伙 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 首席合伙人：高峰 上年度末（2024 年 12 月 31 日）合伙人数量：116 人 上年度末（2024 年 12 月 31 日）注册会计师人数：694 人 上年度末（2024 年 12 月 31 日）签署过证券服务业务审计报告的注册会计 师人数：2 ...

通策医疗股份有限公司 2024年社会责任报告 通策医疗股份有限公司 TOPCHOICE MEDICAL CORPORATION 地址：浙江省杭州市灵溪北路21号合生国贸中心5号楼 邮编：310023 网址：www.tcmedical.com.cn 关于本报告 REGARDING THIS REPORT 本报告是通策医疗股份有限公司发布的 第12份社会责任报告，对外披露本公司 2024年在经济、社会、环境、公司治理 等方面的社会责任理念、实践和相关绩 效。我们期望通过发布社会责任报告的 方式，加强与利益相关方的沟通，凝聚 共识，促进可持续发展。 一、时间范围 本报告时间范围为2024年1月1日至2024年12月31日，部 分内容超出上述范围。 二、组织范围 以通策医疗股份有限公司为主题包括所属分子公司及事业 部等机构。 三、发布周期 通策医疗股份有限公司社会责任报告为年度报告。 四、数据说明 本报告所引用的数据，均来自于公司正式文件、统计报告 或公开文件。 五、参考标准 本报告编写参照中国社科院《中国企业社会责任报告编写 指南》以及上交所《上海证券交易所上市公司环境信息披 露指引》等有关要求。 六、可靠性保证 ...